Data of Merck's pembrolizumab for adjuvant therapy after complete resection of high-risk stage II melanoma patients announced

Shanghai, September 27, 2021/PRNewswire/ - Merck (Merck & Co.

"Through the KEYNOTE-716 study, we hope to explore whether pembrolizumab as an adjuvant therapy can prolong the recurrence-free survival of patients with high-risk stage II melanoma after complete resection

"Patients with melanoma diagnosed with stage IIB and IIC still have a higher risk of recurrence after complete surgical resection, and the five-year survival rate of patients is similar to that of patients with stage IIIA and IIIB

KEYNOTE-716 related data research has been announced at the ESMO chairperson seminar and media conference (Abstract #LBA3)

Up to now, the indications for Pembrolizumab approved by the National Medical Products Administration (NMPA) are:

Applicable to the treatment of unresectable or metastatic melanoma that has failed first-line treatment; Applicable to the detection and evaluation of PD-L1 tumor proportion score (TPS) ≥1% approved by the National Medical Products Administration (EGFR) ) First-line monotherapy for locally advanced or metastatic non-small cell lung cancer with negative gene mutations and anaplastic lymphoma kinase (ALK) negative; combined with pemetrexed and platinum-based chemotherapy is suitable for epidermal growth factor receptor (EGFR) gene mutations Negative and anaplastic lymphoma kinase (ALK) negative metastatic non-squamous non-small cell lung cancer (NSCLC) first-line treatment; combined with carboplatin and paclitaxel is suitable for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) ; Single agent is used to evaluate PD-L1 expression (comprehensive positive score (CPS) ≥ 10) in tumors, previously failed first-line systemic treatments, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients through a fully validated test Treatment; single agent is used to evaluate the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) patients whose tumors express PD-L1 (comprehensive positive score (CPS) ≥ 20) through fully validated tests ; For the first-line treatment of colorectal cancer (CRC) patients with KRAS, NRAS and BRAF genes all wild-type, unresectable or metastatic high microsatellite instability (MSI-H) or mismatch repair gene defect (dMMR) ; Combination of platinum and fluorouracil chemotherapeutics for the first-line treatment of patients with locally advanced unresectable or metastatic esophagus or gastroesophageal junction cancer

Pembrolizumab has not yet been approved by the NMPA for the adjuvant treatment of patients with high-risk stage II melanoma after complete resection

[1] Up to now, the indications of pembrolizumab for adjuvant therapy in patients with high-risk stage II melanoma after complete resection have not been approved by the NMPA

About Merck

For 130 years, Merck has always followed our mission of saving lives and improving lives, committed to enhancing lives, and bringing medicines and vaccines to the world's most difficult diseases

About Merck China

China is a vital part of Merck's global growth strategy

Merck's forward-looking statement

Merck’s global headquarters is located in Kenilworth, New Jersey (hereinafter referred to as the "Company")

Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors (including interest rate and exchange rate fluctuations), the impact of pharmaceutical industry regulations and medical policies in the United States and other countries, the global trend of controlling medical costs, and technological development , New products and patents acquired by competitors, the inherent challenges of new product development (including obtaining regulatory approvals), Merck’s ability to accurately predict the future market situation, difficulties or delays in production, and unstable international economic and financial conditions.

Merck has no obligation to publicly update any forward-looking statements regarding new information, future events or other reasons

Source: Merck China